Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OTT.S60762 http://scihub22266oqcxt.onion/10.2147/OTT.S60762 C4514349!4514349!26229484     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26229484&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26229484.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Onco+Targets+Ther 2015 ; 8 (ä): 1761-71 Nephropedia Template TP {{tp|p=26229484|t=2015. Volasertib for AML: clinical use and patient consideration |pdf=|usr=}}{{26229484}} gab.com Text Volasertib for AML: clinical use and patient consideration JO: Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=26229484 #FOAvip Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy. Twit Text FOAVip Volasertib for AML: clinical use and patient consideration ????Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=26229484 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26229484 #FOAvip English Wikipedia <ref>{{Cite pmid|26229484}}</ref> Volasertib for AML: clinical use and patient consideration #MMPMID26229484 Hao Z; Kota V Onco Targets Ther 2015[]; 8 (ä): 1761-71 PMID26229484show ga Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy. äVolasertib for AML: clinical use and patient consideration (epmc).pdf DeepDyve Pubget Overpricing